Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27652229
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Transl+Androl+Urol
2016 ; 5
(4
): 576-91
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
The drug treatment of delayed ejaculation
#MMPMID27652229
Abdel-Hamid IA
; Elsaied MA
; Mostafa T
Transl Androl Urol
2016[Aug]; 5
(4
): 576-91
PMID27652229
show ga
Delayed ejaculation (DE) is an uncommon and a challenging disorder to treat. It
is often quite concerning to patients and it can affect psychosocial well-being.
Here we reviewed how DE is treated pharmacologically .We also highlighted
specific settings where drugs could be introduced to medical practice. Electronic
databases were searched from 1966 to February 2016, including PubMed MEDLINE,
EMBASE, EBCSO Academic Search Complete, Cochrane Systematic Reviews Database, and
Google Scholar using key words; delayed ejaculation, retarded ejaculation,
inhibited ejaculation, drugs, treatment, or pharmacology. To achieve the maximum
sensitivity of the search strategy and to identify all studies, we combined
"delayed ejaculation" as Medical Subject Headings (MeSH) terms or keywords with
each of "testosterone" or "cabergoline" or "bupropion" or "amantadine" or
"cyproheptadine" or "midodrine" or "imipramine" or "ephedrine" or
"pseudoephedrine" or "yohimbine" or "buspirone" or "oxytocin" or "bethanechol" as
MeSH terms or keywords. There are a number of drugs to treat patients with DE
including: testosterone, cabergoline, bupropion, amantadine, cyproheptadine,
midodrine, imipramine, ephedrine, pseudoephedrine, yohimbine, buspirone,
oxytocin, and bethanechol. Although there are many pharmacological treatment
options, the evidence is still limited to small trials, case series or case
reports. Review of literature showed that evidence level 1 (Double blind
randomized clinical trial) studies were performed with testosterone, oxytocin,
buspirone or bethanechol treatment. It is concluded that successful drug
treatment of DE is still in its infancy. The clinicians need to be aware of the
pathogenesis of DE and the pharmacological basis underlying the use of different
drugs to extend better care for these patients. Various drugs are available to
address such problem, however their evidence of efficacy is still limited and
their choice needs to be individualized to each specific case.
free
free
free
